ORTHOCELL LIMITED — Director's Dealing 2018

May 10, 2018

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	30/11/2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> (Dr Washer is a trustee and beneficiary of the superannuation fund) Mal Washer Nominees Pty Ltd Family A/C> (Dr Washer is a trustee and beneficiary of the trust)
Date of change	9/05/2018
No. of securities held prior to change Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> Dr Washer is a trustee and beneficiary of the superannuation fund)	254,417 Ordinary Shares

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

	Appendix 3Y Change of Director’s Interest Notice
Mal Washer Nominees Pty Ltd Family A/C> Dr Washer is a trustee and beneficiary of the trust)	235,994 Ordinary Shares 95,842 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020
Class	Ordinary Shares Unlisted options
Number acquired	60,000 Ordinary Shares 1,850,000 Unlisted Options
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Ordinary Shares - $0.34 Unlisted Options - Nil
No. of securities held after change Dr Stewart James Washer & Dr Patrizia Derna Washer Fund> Dr Washer is a trustee and beneficiary of the superannuation fund) Mal Washer Nominees Pty Ltd Family A/C> Dr Washer is a trustee and beneficiary of the trust)	314,417 Ordinary Shares 1,850,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 235,994 Ordinary Shares 95,842 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Shares, and Unlisted Options pursuant to the Orthocell Limited Equity Incentive Plan, approved at a General Meeting held on 7 May 2018

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

• See chapter 19 for defined terms.

Appendix

3Y

2

Page

Appendix 3Y Change of Director’s Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Part 3 Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Anderson
Date of last notice	30/11/2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Anderson is a trustee and beneficiary of the Elwing Superannuation Fund Nicole Telford – spouse
Date of change	9/05/2018
No. of securities held prior to change Paul Anderson and Nicole Telford Paul Anderson Nicole Telford Paul Anderson and Nicole Telford (Mr Anderson is a trustee and beneficiary of the Elwing Superannuation Fund)	6,403,335 Ordinary Shares 16 Ordinary Shares 250,000 Unlisted options exercisable at $0.624 on or before 12 October 2019 578,619 Ordinary Shares 13,692 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Class	Ordinary Shares Unlisted options
Number acquired	50,585 Ordinary Shares 3,150,000 Unlisted Options
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Ordinary Shares - $0.34 Unlisted Options - Nil
No. of securities held after change Paul Anderson and Nicole Telford Paul Anderson Nicole Telford Paul Anderson and Nicole Telford (Mr Anderson is a trustee and beneficiary of the Elwing Superannuation Fund)	6,403,335 Ordinary Shares 16 Ordinary Shares 2,300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 250,000 Unlisted options exercisable at $0.624 on or before 12 October 2019 850,0000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018) 629,204 Ordinary Shares 13,692 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Shares, and Unlisted Options pursuant to the Orthocell Limited Equity Incentive Plan, approved at a General Meeting held on 7 May 2018

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Part 3 Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Matthew Callahan
Date of last notice	30/11/2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Callahan is a founder and director of Stone Ridge Ventures Pty Ltd which is the manager of the SRV Tech Trust, a venture capital fund. Mr Callahan is considered to have a relevant interest in these shares due to his position as a director or shareholder of the respective trustee companies and holds a beneficial interest in the SRV Trust. The SRV Trust is the carry trust for the SRV Tech Trust Mr Callahan is a director of the Trustee and a beneficiary of the Shenasaby trust Mr Callahan is a director of the Trustee and a member of the Shenasaby Super Fund
Date of change	9/05/2018

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change (cont’d) SRV Custodians Pty Ltd SRV Nominees Pty Ltd Shenasaby Investments Pty Ltd Shenasaby Investments Pty Ltd as trustee for the Shenasaby Trust	9,530,382 Ordinary Shares 649,177 Ordinary Shares 12,500 Ordinary Shares 27,000 Ordinary Shares
Class	Ordinary Shares Unlisted options
Number acquired	58,823 Ordinary Shares 1,850,000 Unlisted Options
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Ordianry Shares - $0.34 Unlisted Options - Nil
No. of securities held after change SRV Custodians Pty Ltd SRV Nominees Pty Ltd Shenasaby Investments Pty Ltd Shenasaby Investments Pty Ltd as trustee for the Shenasaby Trust	9,530,382 Ordinary Shares 649,177 Ordinary Shares 12,500 Ordinary Shares 85,823 Ordinary Shares 1,850,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Shares, and Unlisted Options pursuant to the Orthocell Limited Equity Incentive Plan, approved at a General Meeting held on 7 May 2018

• See chapter 19 for defined terms.

Appendix 3Y Page 2

Appendix 3Y Change of Director’s Interest Notice

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value / Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Part 3 Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix

3Y

4

Page

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lars Lidgren
Date of last notice	30/11/2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	JP Morgan Nominees Australia Limited Diamonex Ltd managed by Banque Carnegie Luxembourg SA Nominees (Professor Lidgren is a director of Diamonex Ltd) Algora AB (Professor Lidgren is a director of Algora AB Ltd)
Date of change	9/05/2018
No. of securities held prior to change JP Morgan Nominees Australia Limited Diamonex Ltd managed by Banque Carnegie Luxembourg SA Nominees (Professor Lidgren is a director of Diamonex Ltd)	196,000 Ordinary Shares 768,091 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020
Class	Ordinary Shares Unlisted options
Number acquired	44,118 Ordinary Shares 300,000 Unlisted Options

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Ordianry Shares - $0.34 Unlisted Options - Nil
No. of securities held after change JP Morgan Nominees Australia Limited Diamonex Ltd managed by Banque Carnegie Luxembourg SA Nominees (Professor Lidgren is a director of Diamonex Ltd) Algora AB (Professor Lidgren is a director ofAlgora AB Ltd)	240,118 Ordinary Shares 768,091 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Shares, and Unlisted Options pursuant to the Orthocell Limited Equity Incentive Plan, approved at a General Meeting held on 7 May 2018

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

• See chapter 19 for defined terms.

Appendix 2

3Y

Page

Appendix 3Y Change of Director’s Interest Notice

Part 3 Closed Period

art 3 Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearancewasrequired?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Orthocell Limited ABN 57 118 897 135

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Qi Xiao Zhou
Date of last notice	30/11/2017

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.
Date of change	9/05/2018
No. of securities held prior to change Qi Xiao Zhou	5,996,241 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020
Class	Unlisted options
Number acquired	300,000 Unlisted Options
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change Qi Xiao Zhou	5,996,241 Ordinary Shares 54,767 Unlisted Warrants exercisable at $0.58 on or before 19 November 2020 300,000 Unlisted Options exercisable at $0.395 expiring 8 May 2021 (vesting conditions set out in NOM for General Meeting held on 7 May 2018)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Unlisted Options pursuant to the Orthocell Limited Equity Incentive Plan, approved at a General Meeting held on 7 May 2018

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 Closed Period

Part 3 Closed Period
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2